Your browser doesn't support javascript.
loading
Prevalence of disease-causing genes in Japanese patients with BRCA1/2-wildtype hereditary breast and ovarian cancer syndrome.
Kaneyasu, Tomoko; Mori, Seiichi; Yamauchi, Hideko; Ohsumi, Shozo; Ohno, Shinji; Aoki, Daisuke; Baba, Shinichi; Kawano, Junko; Miki, Yoshio; Matsumoto, Naomichi; Nagasaki, Masao; Yoshida, Reiko; Akashi-Tanaka, Sadako; Iwase, Takuji; Kitagawa, Dai; Masuda, Kenta; Hirasawa, Akira; Arai, Masami; Takei, Junko; Ide, Yoshimi; Gotoh, Osamu; Yaguchi, Noriko; Nishi, Mitsuyo; Kaneko, Keika; Matsuyama, Yumi; Okawa, Megumi; Suzuki, Misato; Nezu, Aya; Yokoyama, Shiro; Amino, Sayuri; Inuzuka, Mayuko; Noda, Tetsuo; Nakamura, Seigo.
Afiliação
  • Kaneyasu T; Project for Development of Innovative Research on Cancer Therapeutics, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku Tokyo, Japan.
  • Mori S; Project for Development of Innovative Research on Cancer Therapeutics, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku Tokyo, Japan.
  • Yamauchi H; Department of Breast Surgical Oncology, St. Luke's International Hospital, 10-1 Akashi-cho, Chuo-ku Tokyo, Japan.
  • Ohsumi S; National Hospital Organization Shikoku Cancer Center, 160 Kou, Minamiumemoto-machi, Matsuyama, Ehime Japan.
  • Ohno S; Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku Tokyo, Japan.
  • Aoki D; Department of Obstetrics & Gynecology, Keio University School of Medicine, 35 Shinano-cho, Shinjuku-ku Tokyo, Japan.
  • Baba S; Sagara Hospital, 3-31 Matsubara-cho, Kagoshima, Japan.
  • Kawano J; Sagara Hospital, 3-31 Matsubara-cho, Kagoshima, Japan.
  • Miki Y; Project for Development of Innovative Research on Cancer Therapeutics, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku Tokyo, Japan.
  • Matsumoto N; Department of Human Genetics, Yokohama City University Graduate School of Medicine, Fukuura 3-9, Kanazawa-ku Yokohama, Japan.
  • Nagasaki M; Department of Integrative Genomics, Tohoku Medical Megabank Organization, Tohoku University, 2-1, Seiryo-machi, Aoba-ku, Sendai, Miyagi Japan.
  • Yoshida R; Department of Clinical Genetic Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku Tokyo, Japan.
  • Akashi-Tanaka S; Division of Breast Surgical Oncology, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku Tokyo, Japan.
  • Iwase T; Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku Tokyo, Japan.
  • Kitagawa D; Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku Tokyo, Japan.
  • Masuda K; Department of Obstetrics & Gynecology, Keio University School of Medicine, 35 Shinano-cho, Shinjuku-ku Tokyo, Japan.
  • Hirasawa A; Department of Obstetrics & Gynecology, Keio University School of Medicine, 35 Shinano-cho, Shinjuku-ku Tokyo, Japan.
  • Arai M; Department of Clinical Genetic Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku Tokyo, Japan.
  • Takei J; Department of Breast Surgical Oncology, St. Luke's International Hospital, 10-1 Akashi-cho, Chuo-ku Tokyo, Japan.
  • Ide Y; Division of Breast Surgical Oncology, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku Tokyo, Japan.
  • Gotoh O; Project for Development of Innovative Research on Cancer Therapeutics, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku Tokyo, Japan.
  • Yaguchi N; Project for Development of Innovative Research on Cancer Therapeutics, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku Tokyo, Japan.
  • Nishi M; Sagara Hospital, 3-31 Matsubara-cho, Kagoshima, Japan.
  • Kaneko K; National Hospital Organization Shikoku Cancer Center, 160 Kou, Minamiumemoto-machi, Matsuyama, Ehime Japan.
  • Matsuyama Y; National Hospital Organization Shikoku Cancer Center, 160 Kou, Minamiumemoto-machi, Matsuyama, Ehime Japan.
  • Okawa M; Department of Breast Surgical Oncology, St. Luke's International Hospital, 10-1 Akashi-cho, Chuo-ku Tokyo, Japan.
  • Suzuki M; Department of Breast Surgical Oncology, St. Luke's International Hospital, 10-1 Akashi-cho, Chuo-ku Tokyo, Japan.
  • Nezu A; Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku Tokyo, Japan.
  • Yokoyama S; Division of Breast Surgical Oncology, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku Tokyo, Japan.
  • Amino S; Project for Development of Innovative Research on Cancer Therapeutics, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku Tokyo, Japan.
  • Inuzuka M; Division of Breast Surgical Oncology, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku Tokyo, Japan.
  • Noda T; Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku Tokyo, Japan.
  • Nakamura S; Division of Breast Surgical Oncology, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku Tokyo, Japan.
NPJ Breast Cancer ; 6: 25, 2020.
Article em En | MEDLINE | ID: mdl-32566746
ABSTRACT
Panel sequencing of susceptibility genes for hereditary breast and ovarian cancer (HBOC) syndrome has uncovered numerous germline variants; however, their pathogenic relevance and ethnic diversity remain unclear. Here, we examined the prevalence of germline variants among 568 Japanese patients with BRCA1/2-wildtype HBOC syndrome and a strong family history. Pathogenic or likely pathogenic variants were identified on 12 causal genes for 37 cases (6.5%), with recurrence for 4 SNVs/indels and 1 CNV. Comparisons with non-cancer east-Asian populations and European familial breast cancer cohorts revealed significant enrichment of PALB2, BARD1, and BLM mutations. Younger onset was associated with but not predictive of these mutations. Significant somatic loss-of-function alterations were confirmed on the wildtype alleles of genes with germline mutations, including PALB2 additional somatic truncations. This study highlights Japanese-associated germline mutations among patients with BRCA1/2 wildtype HBOC syndrome and a strong family history, and provides evidence for the medical care of this high-risk population.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prevalence_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prevalence_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article